


## S


### Research Grade Bebtelovimab

<b>Catalog No.</b>	DVV00319A DVV00319B	<b>Quantity:</b>	100 µg 1.0 mg
<b>Alternate Names:</b>	LY-CoV1404, LY3853113		
<b>Description:</b>	<p>LY-CoV1404 (LY3853113) is a fully human anti-SARS-CoV-2 monoclonal antibody, originally derived from plasma of a convalescent patient with Covid-19, selected based on its potential to neutralize the virus in vitro, kill infected cells, provide a high barrier to resistance, and achieve high concentrations in the lungs (one of the major sites of infection). LY-CoV1404 potently neutralizes SARS-CoV-2 authentic virus and all known variants of concern including the B.1.617.2 (Delta) variant and variants of Omicron. Binding epitope on RBD of SARS-CoV-2 is rarely mutated.</p> <p>Bebtelovimab was selected for clinical development based on its potential to both block viral entry into healthy cells and clear infected cells.</p>		
<b>UniProt ID (target):</b>	P0DTC2-2		
<b>Specificity:</b>	Recognizes SARS-CoV-2 (2019-nCoV) Spike-RBD. The RBD positions comprising the LY-CoV1404 epitope are highly conserved.		
<b>Bioactivity:</b>	EC50 = 0.1121 for Omicron RBD		
<b>Source:</b>	XtenCHO		
<b>Purity:</b>	> 95% by reduced and non-reduced SDS-PAGE		
<b>Isotype:</b>	Human IgG1 lambda2		
<b>Clone:</b>	LY-CoV1401 / LY3853113		
<b>Concentration:</b>	1.0 mg/ml, lot specific		
<b>Formulation:</b>	Sterile-filtered 0.01M PBS, pH 7.4		
<b>Purification:</b>	Protein A affinity chromatography		
<b>Endotoxin:</b>	< 0.01 EU/µg by LAL analysis		
<b>Applications:</b>	<b>Neutralization, Functional Studies</b>		
<b>Storage &amp; Stability:</b>	<p>Stable at 2-8°C for 1 week or for up to 1 year at -20°C to -80°C. It is recommended to prepare single-use aliquots of undiluted product and store -20°C to -80°C.</p> <p><b>Avoid repeated freeze/thaw cycles.</b></p>		





Coomassie blue staining non-reduced and reduced SDS-PAGE analysis



NOT FOR HUMAN USE. FOR RESEARCH ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE.

